1-237638480-G-C
Variant summary
Our verdict is Pathogenic. Variant got 13 ACMG points: 13P and 0B. PM1PM2PM5PP2PP3_StrongPP5_Moderate
The ENST00000366574.7(RYR2):c.6916G>C(p.Val2306Leu) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. V2306I) has been classified as Likely pathogenic.
Frequency
Consequence
ENST00000366574.7 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 13 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
RYR2 | NM_001035.3 | c.6916G>C | p.Val2306Leu | missense_variant | 45/105 | ENST00000366574.7 | NP_001026.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
RYR2 | ENST00000366574.7 | c.6916G>C | p.Val2306Leu | missense_variant | 45/105 | 1 | NM_001035.3 | ENSP00000355533 | P1 | |
RYR2 | ENST00000660292.2 | c.6916G>C | p.Val2306Leu | missense_variant | 45/106 | ENSP00000499787 | ||||
RYR2 | ENST00000659194.3 | c.6916G>C | p.Val2306Leu | missense_variant | 45/105 | ENSP00000499653 | ||||
RYR2 | ENST00000609119.2 | c.6916G>C | p.Val2306Leu | missense_variant, NMD_transcript_variant | 45/104 | 5 | ENSP00000499659 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Mar 18, 2013 | p.Val2306Leu (GTC>CTC): c.6916 G>C in exon 45 of the RYR2 gene (NM_001035.2). While the Val2306Leu mutation in the RYR2 gene has not been published to our knowledge, a mutation affecting this same residue (Val2306Ile), has been reported as a de novo mutation in one individual diagnosed with CPVT (Laitinen P et al., 2003). Additionally, mutations in nearby residues (Glu2296Gln, Glu2311Asp, Ala2317Glu) have been reported in association with arrhythmia, further supporting the functional importance of the Val2306 residue and this region of the protein. Although Val2306Leu results in a conservative amino acid substitution of one non-polar amino acid for another, this substitution occurs at a position that is highly conserved across species, and is located in one of three mutation hot spot regions in the RYR2 gene (Medeiros-Domingo A et al., 2009). In silico analysis predicts Val2306Leu is damaging to the protein structure/function. Furthermore, Val2306Leu was not observed in approximately 6000 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. In summary, Val2306Leu in the RYR2 gene is interpreted as a likely disease-causing mutation. Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) is characterized by syncope, typically beginning in the first decade of life, which may be triggered by physical activity or intense emotion. In patients with CPVT, stress-induced release of catecholamines causes a dysfunction of the calcium--ion channel in the myocytes (De La Fuente et al., 2008; Napolitano C et al., 2012; Priori S et al., 2002). CPVT is primarily caused by autosomal dominant mutations in the RYR2 and KCNJ2 genes. Approximately 50% of patients with autosomal dominant CPVT have been reported to have a mutation in the RYR2 gene, while mutations in the RYR2 gene associated with ARVC are rare (McNally E et al., 2009; Napolitano C et al., 2012). The variant is found in ARVC,POSTMORTEM panel(s). - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at